đź•’ Created · Updated

The FDA Approved Rasonque and Daraxonrasib as New Targeted Therapies for Pancreatic Cancer Patients

The U.S. Food and Drug Administration recently approved two significant new medications for pancreatic cancer, a disease known for its high mortality rate and difficulty in early detection. Rasonque, developed by Revolution Medicines, targets the mutated KRAS protein to provide a targeted therapy that doubled the median survival of patients from 6.7 months to 13.2 months. While some patients, such as former Nebraska Senator Ben Sasse, reported experiencing some

Sources